On Friday, Merck & Co Inc (NYSE:MRK) and Eisai Co Ltd (OTC:ESAIY) (OTC:ESALF) announced results from the Phase 3 LEAP-015 trial of Keytruda (pembrolizumab) plus Lenvima (lenvatinib), in combination ...
Merck's KEYLYNK-001 trial showed Keytruda and Lynparza improved progression-free survival in BRCA non-mutated ovarian cancer patients. In the waveLINE-007 trial, zilovertamab vedotin with R-CHP ...
Even for Merck’s oncology powerhouse Keytruda, the emerging role of immunotherapies in gynecological cancer treatment represents a bit of a mixed bag. While earlier this year Keytruda seemed to shine ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
J&J’s Mixed Q4 Results: J&J reported mixed fourth-quarter results as it beat estimates for earnings but missed the same for sales. Currency headwinds reduced its total sales by more than 5% in the ...
On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results